Under construction – not a live service
Sign in
Not yet taking people in ChinaNo phase

Wearable monitors and digital rehabilitation after two-stage surgery for multiple lung cancers

Tests whether wearable monitoring and digital rehabilitation speed recovery between two lung cancer operations.

Key facts

Who runs it
West China Hospital
Where
Chengdu, ChinaSee the site
Trial code
Registry title
Digital Rehabilitation With Wearable Monitors for Sequential Lung Cancer Resection
Status
Not yet recruiting
People taking part
222 people, planned
Started
31 Aug 2026
Expected to end
31 Aug 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Wireless Wearable Vital Sign and Activity Monitor
  • Digital Pulmonary Rehabilitation Program
  • Standard ERAS Perioperative and Rehabilitation Care
Record updated
1 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with more than one primary non-small cell lung cancer who are having two planned operations. It tests a rehab program with wearable monitors after the first surgery.

Age
18 to 85 years
Sex
All sexes can join.
Disease stage
Confirmed multiple primary non-small cell lung cancer (one or both lungs). First surgery (lobectomy or segmentectomy) done or planned within 7 days after enrolment. Second surgery planned within 12 weeks after the first.
Earlier treatment
No prior treatment is required. The first-stage surgery has been done or is planned within 7 days after enrolment.

Main reasons for not taking part

  • Long-term home oxygen therapy, or severe low oxygen or breathing problems at rest
  • Severe uncontrolled heart disease, or severe liver or kidney failure
  • Conditions that strongly affect movement or the ability to take part, such as severe nerve, muscle or bone disease, memory problems or major mental illness
  • Allergy to the medical adhesives or electrode materials, or skin that cannot hold the device
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age ≥18 and ≤85 years
  • Histopathologically confirmed primary non-small cell lung cancer (NSCLC) meeting diagnostic criteria for multiple primary lung cancer (MPLC, unilateral or bilateral multifocal lesions), scheduled for elective sequential (two-stage) curative-intent resection; the first-stage surgery (lobectomy or segmentectomy) has been performed or is planned within 7 days after enrollment, with the second-stage surgery planned within 12 weeks postoperatively
  • Planned discharge between postoperative day 2 and day 7, and judged by the investigator to be clinically stable and suitable for home-based/out-of-hospital rehabilitation
  • Able to operate a smartphone application and wearable devices independently or with caregiver assistance, with stable cellular/broadband network access
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and preoperatively assessed as able to tolerate routine rehabilitation training
  • Intact skin at the wearable device attachment sites, without severe skin diseases affecting device placement
  • Willing and able to provide written informed consent

Who cannot take part

  • Pre-existing long-term home oxygen therapy, or severe resting hypoxemia/ventilatory dysfunction (judged by the investigator to persistently affect safe rehabilitation)
  • Concurrent severe, uncontrolled cardiovascular disease (e.g., unstable angina, acute myocardial infarction or stroke within 3 months, NYHA class III-IV heart failure), severe hepatic insufficiency, or severe renal insufficiency
  • Concurrent participation in another interventional clinical trial that may interfere with the outcomes of this study
  • Other diseases or conditions that significantly affect motor function or compliance (e.g., severe neuromuscular/skeletal disorders, cognitive impairment, major psychiatric disorders)
  • Known or suspected contact allergy to medical adhesives or electrode materials used in the wearable devices, or skin conditions unsuitable for prolonged device attachment
  • Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation
  • Presence of implanted medical devices incompatible with the study wearable devices, or other contraindications as specified in the device instructions
  • Pregnancy or lactation, or women of childbearing potential who are unwilling to adopt effective contraceptive measures during the study period

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where in China

  • West China HospitalChengdu, ChinaContact: Xuelei maNo longer taking part

About the trial

What the trial wants to find out

This is a prospective, open-label, parallel-group, 1:1 randomized controlled trial designed to evaluate whether a digital rehabilitation program integrated with wireless wearable continuous monitoring devices can shorten the time to functional recovery in patients with multiple primary non-small cell lung cancer (MPLC) who undergo sequential (two-stage) curative-intent resection.

Read full original descriptionShow less

Eligible participants will be randomly assigned to either the intervention group or the control group. Both groups will receive standard enhanced recovery after surgery (ERAS) care. In addition, the intervention group will receive continuous vital sign monitoring (using a wearable patch during hospitalization and a wrist-worn device after discharge), personalized exercise prescriptions with daily step targets, and high-frequency electronic patient-reported outcome (ePRO) follow-up with threshold-triggered response. The control group will receive standard intermittent vital sign monitoring and conventional rehabilitation education.

The primary endpoint is the time from the first surgery to attainment of functional recovery criteria sufficient for second-stage surgery readiness (assessed by a composite of step count recovery, functional interference score combined with 6-minute walk distance, or multidisciplinary team determination). Secondary endpoints include pulmonary function recovery (FEV1%, FVC%, DLCO% at 3 months), physical activity (daily steps, moderate-to-vigorous physical activity, 6-minute walk distance), symptom burden and quality of life (EORTC QLQ-C30/LC13, PROMIS), 30- and 90-day complication and readmission rates, second-surgery-related outcomes, adherence, safety, and healthcare resource utilization.

A total of 222 participants (111 per group) will be enrolled. The study will be conducted at West China Hospital of Sichuan University from June 2026 to October 2027. The findings are expected to provide high-quality evidence on the clinical utility of wearable-integrated digital rehabilitation in the perioperative management of MPLC patients undergoing sequential resection.

The 2 groups in the trial

  • Digital Rehabilitation with Wearable MonitoringTreatment being tested

    Participants receive standard ERAS/ERATS perioperative care plus a wireless wearable mobile monitoring and digital rehabilitation program. This includes: (1) continuous vital sign monitoring via a wearable patch during hospitalization and a wrist-worn activity tracker after discharge; (2) personalized exercise prescriptions (aerobic, resistance, and inspiratory muscle training) with progressive step goals; (3) high-frequency electronic patient-reported outcome (ePRO) symptom surveillance; and (4) threshold-triggered graded responses (e.g., SpO₂ \<90%, persistent tachycardia, symptom escalation) prompting telephone follow-up, outpatient visit, or emergency care.

    Treatment: Wireless Wearable Vital Sign and Activity Monitor and Digital Pulmonary Rehabilitation Program

  • Standard ERAS Perioperative CareExisting treatment, for comparison

    Participants receive standard perioperative care and conventional rehabilitation education according to institutional practice. This includes routine intermittent vital sign monitoring during hospitalization and standard follow-up visits. No continuous wearable monitoring or digital rehabilitation prescription is provided.

    Treatment: Standard ERAS Perioperative and Rehabilitation Care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Clinical Trial of Rehabilitation During Sequential Resection of Multiple Primary Non-Small Cell Lung Cancer Based on Wireless Wearable Mobile Monitoring Devices
Plain-language title
Wearable monitors and digital rehabilitation after two-stage surgery for multiple lung cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07797075, who can take part
Record updated
1 September 2026